Trademark: 97052171
Word
NEOFORDEX
Status
Registered
Status Code
700
Status Date
Tuesday, November 1, 2022
Serial Number
97052171
Registration Number
6888402
Registration Date
Tuesday, November 1, 2022
Mark Type
4000
Filing Date
Wednesday, September 29, 2021
Published for Opposition
Tuesday, August 16, 2022

Trademark Owner History
LABORATOIRES C.T.R.S. - Original Registrant

Classifications
5 Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, namely, amyloses, and purpura, namely, thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia. chemical preparations for medical and pharmaceutical use for treating haematological diseases, namely, amyloses, and purpura, especially thrombocytopenic purpura

Trademark Events
Nov 1, 2022
Notice Of Registration Confirmation Emailed
Nov 1, 2022
Registered-Principal Register
Aug 16, 2022
Official Gazette Publication Confirmation E-Mailed
Aug 16, 2022
Published For Opposition
Jul 27, 2022
Notification Of Notice Of Publication E-Mailed
Jul 14, 2022
Approved For Pub - Principal Register
Jul 13, 2022
Teas/Email Correspondence Entered
Jul 12, 2022
Correspondence Received In Law Office
Jul 12, 2022
Teas Response To Office Action Received
Jul 5, 2022
Notification Of Non-Final Action E-Mailed
Jul 5, 2022
Non-Final Action E-Mailed
Jul 5, 2022
Non-Final Action Written
Jun 29, 2022
Assigned To Examiner
Oct 27, 2021
New Application Office Supplied Data Entered In Tram
Oct 2, 2021
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24